Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment
S Boopathi, AB Poma, P Kolandaivel - Journal of Biomolecular …, 2021 - Taylor & Francis
In the past two decades, the world has faced several infectious disease outbreaks. Ebola,
Influenza A (H1N1), SARS, MERS, and Zika virus have had a massive global impact in terms …
Influenza A (H1N1), SARS, MERS, and Zika virus have had a massive global impact in terms …
Recent discovery and development of inhibitors targeting coronaviruses
T Pillaiyar, S Meenakshisundaram, M Manickam - Drug discovery today, 2020 - Elsevier
Human coronaviruses (CoVs) are enveloped viruses with a positive-sense single-stranded
RNA genome. Currently, six human CoVs have been reported including human coronavirus …
RNA genome. Currently, six human CoVs have been reported including human coronavirus …
[HTML][HTML] Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
A new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), is the aetiological agent responsible for the 2019–2020 viral pneumonia outbreak of …
2), is the aetiological agent responsible for the 2019–2020 viral pneumonia outbreak of …
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is the etiological agent
responsible for the global COVID-19 (coronavirus disease 2019) outbreak. The main …
responsible for the global COVID-19 (coronavirus disease 2019) outbreak. The main …
Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur
The antineoplastic drug carmofur is shown to inhibit the SARS-CoV-2 main protease (Mpro).
Here, the X-ray crystal structure of Mpro in complex with carmofur reveals that the carbonyl …
Here, the X-ray crystal structure of Mpro in complex with carmofur reveals that the carbonyl …
Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities
The newly emerged coronavirus, called SARS-CoV-2, is the causing pathogen of pandemic
COVID-19. The identification of drugs to treat COVID-19 and other coronavirus diseases is …
COVID-19. The identification of drugs to treat COVID-19 and other coronavirus diseases is …
Potential SARS-CoV-2 main protease inhibitors
R Banerjee, L Perera, LMV Tillekeratne - Drug Discovery Today, 2021 - Elsevier
Highlights•The SARS-CoV-2 main protease is a prime drug target.•Coronavirus main
proteases share a structurally conserved substrate-binding region.•The structure and …
proteases share a structurally conserved substrate-binding region.•The structure and …
Inhibition of SARS-CoV 3CL protease by flavonoids
S Jo, S Kim, DH Shin, MS Kim - Journal of enzyme inhibition and …, 2020 - Taylor & Francis
There were severe panics caused by Severe Acute Respiratory Syndrome (SARS) and
Middle-East Respiratory Syndrome-Coronavirus. Therefore, researches targeting these …
Middle-East Respiratory Syndrome-Coronavirus. Therefore, researches targeting these …
Coronaviruses—drug discovery and therapeutic options
In humans, infections with the human coronavirus (HCoV) strains HCoV-229E, HCoV-OC43,
HCoV-NL63 and HCoV-HKU1 usually result in mild, self-limiting upper respiratory tract …
HCoV-NL63 and HCoV-HKU1 usually result in mild, self-limiting upper respiratory tract …
Exploring the binding mechanism of PF-07321332 SARS-CoV-2 protease inhibitor through molecular dynamics and binding free energy simulations
The novel coronavirus disease, caused by severe acute respiratory coronavirus 2 (SARS-
CoV-2), rapidly spreading around the world, poses a major threat to the global public health …
CoV-2), rapidly spreading around the world, poses a major threat to the global public health …